Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

A randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor was conducted through the T-20 vs. Optimized Regimen Only Study 1 (TORO 1). It was concluded that the addition of enfuvirtide to an optimized antiretroviral regimen provided significant antiretroviral and immunologic benefit through 24 weeks in patients who had previously received multiple antiretroviral drugs and had multidrug-resistant HIV-1 infection.